Update on Chlamydia trachomatis vaccinology

Luis M. De La Maza, Guangming Zhong, Robert C. Brunham

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations


Attempts to produce a vaccine to protect against Chlamydia trachomatisinduced trachoma were initiated more than 100 years ago and continued for several decades. Using whole organisms, protective responses were obtained. However, upon exposure to C. trachomatis, disease exacerbation developed in some immunized individuals, precluding the implementation of the vaccine. Evidence of the role of C. trachomatis as a sexually transmitted pathogen started to emerge in the 1960s, and it soon became evident that it can cause acute infections and long-term sequelae in women, men, and newborns. The main focus of this minireview is to summarize recent findings and discuss formulations, including antigens, adjuvants, routes, and delivery systems for immunization, primarily explored in the female mouse model, with the goal of implementing a vaccine against C. trachomatis genital infections.

Original languageEnglish (US)
Article number0054316
JournalClinical and Vaccine Immunology
Issue number4
StatePublished - Apr 2017


  • Adjuvants
  • Antigens
  • Chlamydia muridarum
  • Chlamydia trachomatis
  • Chlamydia trachomatis vaccines
  • Delivery systems
  • Routes of immunization
  • Vaccinology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)


Dive into the research topics of 'Update on Chlamydia trachomatis vaccinology'. Together they form a unique fingerprint.

Cite this